Quick Answer
Inhibrx Biosciences, Inc. reported R&D Expense of $113.03 million for fiscal year 2025.
Inhibrx Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $113.03M | -44.5% |
| 2024 | $203.74M | +6.3% |
| 2023 | $191.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.54M | -26.6% | +28.1% |
| June 30, 2025 | $22.27M | -67.1% | -39.6% |
| March 31, 2025 | $36.88M | -42.2% | -5.2% |
| September 30, 2024 | $38.89M | +2.2% | -42.5% |
| June 30, 2024 | $67.63M | +98.3% | +5.9% |
| March 31, 2024 | $63.85M | — | +67.8% |
| September 30, 2023 | $38.06M | — | +11.6% |
| June 30, 2023 | $34.11M | — | — |
- Inhibrx Biosciences, Inc. showed a decrease of -44.5% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s r&d expense has declined by 41.0% (from $191.64 million to $113.03 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: